Condensed Balance Sheets - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 20,530,960	$ 9,968,600
Short-term investments available-for-sale, at fair value	25,125,209
Accounts receivable	2,836,526	6,356,268
Contract assets	167,835
Inventory, net of allowance of $63,943 at March 31, 2018 and $62,142 at December 31, 2017	1,042,017	1,180,521
Prepaid expenses and other	464,562	443,068
Total current assets	50,167,109	17,948,457
Deferred offering costs		2,953
Deferred MidCap revolving loan costs	79,197
Property and equipment, net	3,099,479	3,304,890
Total assets	53,345,785	21,256,300
Current liabilities:
Accounts payable	2,216,115	2,438,798
Accrued liabilities	1,681,183	3,746,786
Contract liabilities - current	462,934	665,882
NuvoGen obligation - current	560,668	496,442
Growth Term Loan payable - net of discount and debt issuance costs		5,793,599
Other current liabilities	202,564	200,460
Total current liabilities	5,123,464	13,341,967
NuvoGen obligation - non-current, net of discount	7,268,161	7,520,913
Convertible note, related party - net of debt issuance costs	2,964,123	2,960,760
MidCap Term Loan payable - net of discount and debt issuance costs	6,585,731
Other non-current liabilities	435,017	492,197
Total liabilities	22,376,496	24,315,837
Commitments and Contingencies (Note 13)
Stockholders’ equity (deficit):
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2018 and December 31, 2017, 28,358,925 shares issued and outstanding at March 31, 2018 and 13,929,763 shares issued and outstanding at December 31, 2017	28,359	13,929
Additional paid-in-capital	170,898,089	131,492,595
Accumulated other comprehensive loss	(11,151)
Accumulated deficit	(139,946,008)	(134,566,061)
Total stockholders’ equity (deficit)	30,969,289	(3,059,537)
Total liabilities and stockholders' equity (deficit)	$ 53,345,785	$ 21,256,300